Drug intelligence / Profile preview

NTCB02-1

Development stage: Phase 3
Lead developer: Yuhan
Administration: Intravenous

Overview

NTCB02-1 is an investigational drug developed by Yuhan Corp. It is currently in Phase 3 clinical trials for use as a dietary supplement in patients who require parenteral nutrition. The specific mechanism of action and molecular target have not been disclosed publicly. The drug is being evaluated for its safety and efficacy compared to NTCB-C in this patient population[1][2][3]. No additional details regarding its composition, modality, or pharmacological class are available from public sources.

Beyond the preview

Go deeper on NTCB02-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTCB02-1.

Explore the full profile